Features and roles of T helper 9 cells and interleukin 9 in immunological diseases
Main Article Content
Keywords
TH9 cells, IL-9, Autoimmunity, Allergic, Infections, Cancer, Immunodeficiency
Abstract
T helper 9 (TH9) cells are considered as newly classified helper T cells that have an important role in the regulation of immune responses. Since these cells preferentially produce IL-9, these cells are termed TH9 cells. Recently, the role of TH9 and its signature cytokine (IL-9) has been investigated in a wide range of diseases, including autoimmunity, allergy, infections, cancer and immunodeficiency. Herein, we review the most recent data concerning TH9 cells and IL-9 as well as their roles in disease. These insights suggest that TH9 cells are a future target for therapeutic intervention.
References
1. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol. 2010;28:445-89.
2. Yamane H, Paul WE. Early signaling events that underlie fate decisions of naive CD4(+) T cells toward distinct T-helper cell subsets. Immunol Rev. 2013;252:12-23.
3. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, et al. Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol. 2008;9: 1341-6.
4. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(−) effector T cells. Nat Immunol. 2008;9:1347-55.
5. Schmitt E, Van Brandwijk R, Van Snick J, Siebold B, Rude E. TCGF III/P40 is produced by naive murine CD4+ T cells but is not a general T cell growth factor. Eur J Immunol. 1989;19:2167-70.
6. Schmitt E, Germann T, Goedert S, Hoehn P, Huels C, Koelsch S, et al. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGFbeta and IL-4, and is inhibited by IFN-gamma. J Immunol. 1994;153:3989-96.
7. Stassen M, Schmitt E, Bopp T. From interleukin-9 to T helper 9 cells. Ann N Y Acad Sci. 2012;1247:56-68.
8. Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol. 2010;10:683-7.
9. Hültner L, Druez C, Moeller J, Uyttenhove C, Schmitt E, Rüde E, et al. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol. 1990;2:1413-6.
10. Mock BA, Krall M, Kozak CA, Nesbitt MN, McBride OW, Renauld JC, et al. IL9 maps to mouse chromosome 13 and human chromosome 5. Immunogenetics. 1990;31:265-70.
11. Renauld J-C, Goethals A, Houssiau F, Merz H, Van Roost E, Van Snick J. Human P40/IL-9. Expression in activated CD4+ T cells, genomic organization, and comparison with the mouse gene. J Immunol. 1990;144:4235-41.
12. Renauld JC, Druez C, Kermouni A, Houssiau F, Uyttenhove C, Van Roost E, et al. Expression cloning of the murine and human interleukin 9 receptor cDNAs. Proc Natl Acad Sci U S A. 1992;89:5690-4.
13. Idzerda RL, March CJ, Mosley B, Lyman SD, Bos TV, Gimpel SD, et al. Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J Exp Med. 1990;171:861-73.
14. Druez C, Coulie P, Uyttenhove C, Van Snick J. Functional and biochemical characterization of mouse P40/IL-9 receptors. J Immunol. 1990;145:2494-9.
15. Cosmi L, Liotta F, Angeli R, Mazzinghi B, Santarlasci V, Manetti R, et al. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood. 2004;103:3117-21.
16. Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, Schreiner B, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med. 2009;206:1653-60.
17. Fawaz LM, Sharif-Askari E, Hajoui O, Soussi-Gounni A, Hamid Q, Mazer BD. Expression of IL-9 receptor alpha chain on human germinal center B cells modulates IgE secretion. J Allergy Clin Immunol. 2007;120:1208-15.
18. Goswami R, Kaplan MH. A brief history of IL-9. J Immunol. 2011;186:3283-8.
19. Demoulin J-B, Uyttenhove C, Van Roost E, DeLestré B, Donckers D, Van Snick J, et al. A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9. Mol Cell Biol. 1996;16: 4710-6.
20. Demoulin JB, Van Roost E, Stevens M, Groner B, Renauld JC. Distinct roles for STAT1, STAT3, and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9. J Biol Chem. 1999;274:25855-61.
21. Yin T, Keller SR, Quelle FW, Witthuhn BA, Tsang ML-S, Lienhard GE, et al. Interleukin-9 induces tyrosine phosphorylation of insulin receptor substrate-1 via JAK tyrosine kinases. J Biol Chem. 1995;270:20497-502.
22. Demoulin J-B, Louahed J, Dumoutier L, Stevens M, Renauld JC. MAP kinase activation by interleukin-9 in lymphoid and mast cell lines. Oncogene. 2003;22:1763-70.
23. Gessner A, Blum H, Röllinghoff M. Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice. Immunobiology. 1993;189:419-35.
24. Dugas B, Renauld JC, Pène J, Bonnefoy JY, Peti-Frère C, Braquet P, et al. Interleukin-9 potentiates the interleukin-4- induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. Eur J Immunol. 1993;23:1687-92.
25. Lu L-F, Lind EF, Gondek DC, Bennett KA, Gleeson MW, PinoLagos K, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature. 2006;442:997-1002.
26. Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola J, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A. 2009;106:12885-90.
27. Beriou G, Bradshaw EM, Lozano E, Costantino CM, Hastings WD, Orban T, et al. TGF-beta induces IL-9 production from human Th17 cells. J Immunol. 2010;185:46-54.
28. Putheti P, Awasthi A, Popoola J, Gao W, Strom TB. Human CD4 memory T cells can become CD4 IL-9+ T cells. PLoS ONE. 2010;5:e8706.
29. Beriou G, Bradshaw EM, Lozano E, Costantino CM, Hastings WD, Orban T, et al. TGF- induces IL-9 production from human Th17 cells. J Immunol. 2010;185:46-54.
30. Wong MT, Ye JJ, Alonso MN, Landrigan A, Cheung RK, Engleman E, et al. Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol cell Biol. 2010;88:624-31.
31. Jones TG, Hallgren J, Humbles A, Burwell T, Finkelman FD, Alcaide P, et al. Antigen-induced increases in pulmonary mast cell progenitor numbers depend on IL-9 and CD1d-restricted NKT cells. J Immunol. 2009;183:5251-60.
32. Lauwerys BR, Garot N, Renauld J-C, Houssiau FA. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol. 2000;165:1847-53.
33. Farahani R, Sherkat R, Hakemi MG, Eskandari N, Yazdani R. Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma. Adv Biomed Res. 2014;3:127.
34. Stassen M, Müller C, Arnold M, Hültner L, Klein-Hessling S, Neudörfl C, et al. IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-B is decisively involved in the expression of IL-9. J Immunol. 2001;166:4391-8.
35. Stassen M, Arnold M, Hültner L, Müller C, Neudörfl C, Reineke T, et al. Murine bone marrow-derived mast cells as potent producers of IL-9: costimulatory function of IL-10 and kit ligand in the presence of IL-1. J Immunol. 2000;164:5549-55.
36. Hültner L, Kölsch S, Stassen M, Kaspers U, Kremer J-P, Mailhammer R, et al. Inactivated mast cells, IL-1 up-regulates the production of several Th2-related cytokines including IL-9. J Immunol. 2000;164:5556-63.
37. Wiener Z, Falus A, Toth S. IL-9 increases the expression of several cytokines in activated mast cells, while the IL-9-induced IL-9 production is inhibited in mast cells of histamine-free transgenic mice. Cytokine. 2004;26:122-30.
38. Wilhelm C, Hirota K, Stieglitz B, Van Snick J, Tolaini M, Lahl K, et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol. 2011;12:1071-7.
39. Sugimoto T, Ishikawa Y, Yoshimoto T, Hayashi N, Fujimoto J, Nakanishi K. Interleukin 18 acts on memory T helper cells type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse. J Exp Med. 2004;199:535-45.
40. Hayashi N, Yoshimoto T, Izuhara K, Matsui K, Tanaka T, Nakanishi K. T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN- and IL-13 production. Proc Natl Acad Sci U S A. 2007;104:14765-70.
41. Gloghini A, Bongarzone I, editors. Cell-secreted signals shape lymphoma identity. Semin Cancer Biol. 2015;34:81-91.
42. Mahnke YD, Beddall MH, Roederer M. OMIP-017: human CD4+ helper T-cell subsets including follicular helper cells. Cytometry A. 2013;83:439-40.
43. Keating P, Munim A, Hartmann JX. Effect of vitamin D on T-helper type 9 polarized human memory cells in chronic persistent asthma. Ann Allergy Asthma Immunol. 2014;112:154-62.
44. Ye Z-J, Yuan M-L, Zhou Q, Du R-H, Yang W-B, Xiong X-Z, et al. Differentiation and recruitment of Th9 cells stimulated by pleural mesothelial cells in human Mycobacterium tuberculosis infection. PLoS ONE. 2012;7:e31710.
45. Ye Z-J, Zhou Q, Yin W, Yuan M-L, Yang W-B, Xiong X-Z, et al. Differentiation and immune regulation of IL-9− producing CD4+ T cells in malignant pleural effusion. Am J Respir Crit Care Med. 2012;186:1168-79.
46. Tan C, Gery I. The unique features of Th9 cells and their products. Crit Rev Immunol. 2012;32:1-10.
47. Tan C, Aziz MK, Lovaas JD, Vistica BP, Shi G, Wawrousek EF, et al. Antigen-specific Th9 cells exhibit uniqueness in their kinetics of cytokine production and short retention at the inflammatory site. J Immunol. 2010;185:6795-801.
48. Jäger A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol. 2009;183:7169-77.
49. Végran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, et al. The transcription factor IRF1 dictates the IL-21- dependent anticancer functions of TH9 cells. Nat Immunol. 2014;15:758-66.
50. Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531-64.
51. Murugaiyan G, Beynon V, Da Cunha AP, Joller N, Weiner HL. IFN- limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J Immunol. 2012;189:5277-83.
52. Liao W, Spolski R, Li P, Du N, West EE, Ren M, et al. Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc Natl Acad Sci U S A. 2014;111:3508-13.
53. Angkasekwinai P, Chang SH, Thapa M, Watarai H, Dong C. Regulation of IL-9 expression by IL-25 signaling. Nat Immunol. 2010;11:250-6.
54. Pan H-F, Leng R-X, Li X-P, Zheng SG, Ye D-Q. Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases. Cytokine Growth Factor Rev. 2013;24:515-22.
55. Uyttenhove C, Brombacher F, Van Snick J. TGF- interactions with IL-1 family members trigger IL-4-independent IL-9 production by mouse CD4+ T cells. Eur J Immunol. 2010;40:2230-5.
56. Yao W, Zhang Y, Jabeen R, Nguyen ET, Wilkes DS, Tepper RS, et al. Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP. Immunity. 2013;38:360-72.
57. Kaplan MH, Hufford MM, Olson MR. The development and in vivo function of T helper 9 cells. Nat Rev Immunol. 2015;15:295-307.
58. Jones CP, Gregory LG, Causton B, Campbell GA, Lloyd CM. Activin A and TGF- promote T H 9 cell-mediated pulmonary allergic pathology. J Allergy Clin Immunol. 2012;129:1000-10.
59. Richard AC, Tan C, Hawley ET, Gomez-Rodriguez J, Goswami R, Yang X-P, et al. The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells. J Immunol. 2015;194:3567-82.
60. Zhao P, Xiao X, Ghobrial RM, Li XC. IL-9 and Th9 cells: progress and challenges. Int Immunol. 2013;25:547-51.
61. Xiao X, Balasubramanian S, Liu W, Chu X, Wang H, Taparowsky EJ, et al. OX40 signaling favors the induction of TH9 cells and airway inflammation. Nat Immunol. 2012;13:981-90.
62. Tone M, Tone Y, Adams E, Yates SF, Frewin MR, Cobbold SP, et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A. 2003;100:15059-64.
63. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol. 2003;3:609-20.
64. Xiao X, Shi X, Fan Y, Zhang X, Wu M, Lan P, et al. GITR subverts Foxp3(+) Tregs to boost Th9 immunity through regulation of histone acetylation. Nat Commun. 2015;6:8266.
65. Kim I-K, Kim B-S, Koh C-H, Seok J-W, Park J-S, Shin K-S, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein co stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. Nat Med. 2015;21:1010-7.
66. Amsen D, Antov A, Flavell RA. The different faces of Notch in Thelper-cell differentiation. Nat Rev Immunol. 2009;9:116-24.
67. Elyaman W, Bassil R, Bradshaw EM, Orent W, Lahoud Y, Zhu B, et al. Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity. 2012;36:623-34.
68. Kerzerho J, Maazi H, Speak AO, Szely N, Lombardi V, Khoo B, et al. Programmed cell death ligand 2 regulates T H 9 differentiation and induction of chronic airway hyperreactivity. J Allergy Clin Immunol. 2013;131:1048-57.
69. Li H, Edin ML, Bradbury JA, Graves JP, DeGraff LM, Gruzdev A, et al. Cyclooxygenase-2 inhibits T helper cell type 9 differentiation during allergic lung inflammation via down-regulation of IL-17RB. Am J Respir Crit Care Med. 2013;187:812-22.
70. Chang H-C, Sehra S, Goswami R, Yao W, Yu Q, Stritesky GL, et al. The transcription factor PU. 1 is required for the development of IL-9 producing T cells and allergic inflammation. Nat Immunol. 2010;11:527-34.
71. Ramming A, Druzd D, Leipe J, Schulze-Koops H, Skapenko A. Maturation-related histone modifications in the PU.1 promoter regulate Th9-cell development. Blood. 2012;119:4665-74.
72. Koh B, Hufford MM, Pham D, Olson MR, Wu T, Jabeen R, et al. The ETS family transcription factors Etv5 and PU.1 function in parallel to promote Th9 cell development. J Immunol. 2016;197:2465-72.
73. Goswami R, Jabeen R, Yagi R, Pham D, Zhu J, Goenka S, et al. STAT6-dependent regulation of Th9 development. J Immunol. 2012;188:968-75.
74. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996;4:313-9.
75. Staudt V, Bothur E, Klein M, Lingnau K, Reuter S, Grebe N, et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity. 2010;33: 192-202.
76. Maruyama T, Li J, Vaque JP, Konkel JE, Wang W, Zhang B, et al. Control of the differentiation of regulatory T cells and TH17 cells by the DNA-binding inhibitor Id3. Nat Immunol. 2011;12:86-95.
77. Nakatsukasa H, Zhang D, Maruyama T, Chen H, Cui K, Ishikawa M, et al. The DNA-binding inhibitor Id3 regulates IL-9 production in CD4+ T cells. Nat Immunol. 2015;16:1077-84.
78. Deng Y, Wang Z, Chang C, Lu L, Lau CS, Lu Q. Th9 cells and IL-9 in autoimmune disorders: pathogenesis and therapeutic potentials. Hum Immunol. 2017;78:120-8.
79. Bassil R, Orent W, Olah M, Kurdi AT, Frangieh M, Buttrick T, et al. BCL6 controls Th9 cell development by repressing Il9 transcription. J Immunol. 2014;193:198-207.
80. Hermann-Kleiter N, Baier G. NFAT pulls the strings during CD4+ T helper cell effector functions. Blood. 2010;115:2989-97.
81. Perumal NB, Kaplan MH. Regulating Il9 transcription in T helper cells. Trends Immunol. 2011;32:146-50.
82. Jash A, Sahoo A, Kim G-C, Chae C-S, Hwang J-S, Kim J-E, et al. Nuclear factor of activated T cells 1 (NFAT1)-induced permissive chromatin modification facilitates nuclear factor-B (NF-B)-mediated interleukin-9 (IL-9) transactivation. J Biol Chem. 2012;287:15445-57.
83. Kadereit S, Mohammad SF, Miller RE, Woods KD, Listrom CD, McKinnon K, et al. Reduced NFAT1 protein expression in human umbilical cord blood T lymphocytes. Blood. 1999;94:3101-7.
84. Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, Wang X-F. Targeted disruption of Smad3 reveals an essential role in transforming growth factor -mediated signaltransduction. Mol Cell Biol. 1999;19:2495-504.
85. Tamiya T, Ichiyama K, Kotani H, Fukaya T, Sekiya T, Shichita T, et al. Smad2/3 and IRF4 play a cooperative role in IL-9- producing T cell induction. J Immunol. 2013;191:2360-71.
86. Kaplan MH. Th9 cells: differentiation and disease. Immunol Rev. 2013;252:104-15.
87. Wang A, Pan D, Lee Y-H, Martinez GJ, Feng X-H, Dong C. Cutting edge: Smad2 and Smad4 Regulate TGF--mediated Il9 gene expression via EZH2 displacement. J Immunol. 2013;191:4908-12.
88. Jabeen R, Goswami R, Awe O, Kulkarni A, Nguyen ET, Attenasio A, et al. Th9 cell development requires a BATF-regulated transcriptional network. J Clin Invest. 2013;123:4641.
89. Echlin DR, Tae H-J, Mitin N, Taparowsky EJ. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos. Oncogene. 2000;19:1752-63.
90. Vegran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, et al. The transcription factor IRF1 dictates the IL-21- dependent anticancer functions of TH9 cells. Nat Immunol. 2014;15:758-66.
91. Yang H, Bi Y, Xue L, Wang J, Lu Y, Zhang Z, et al. Multifaceted modulation of SIRT1 in cancer and inflammation. Crit Rev Oncog. 2015;20:49-64.
92. Wang Y, Bi Y, Chen X, Li C, Li Y, Zhang Z, et al. Histone deacetylase SIRT1 negatively regulates the differentiation of interleukin-9-producing CD4+ T cells. Immunity. 2016;44:1337-49.
93. Berg LJ, Finkelstein LD, Lucas JA, Schwartzberg PL. Tec family kinases in T lymphocyte development and function. Annu Rev Immunol. 2005;23:549-600.
94. Gomez-Rodriguez J, Meylan F, Handon R, Hayes ET, Anderson SM, Kirby MR, et al. Itk is required for Th9 differentiation via TCR-mediated induction of IL-2 and IRF4. Nat Commun. 2016:7.
95. Kim HY, DeKruyff RH, Umetsu DT. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat
Immunol. 2010;11:577---84.
96. Yu S, Kim HY, Chang Y-J, DeKruyff RH, Umetsu DT. Innate lymphoid cells and asthma. J Allergy Clin Immunol. 2014;133:943-50.
97. Yazdani R, Sharifi M, Shirvan AS, Azizi G, Ganjalikhani-Hakemi M. Characteristics of innate lymphoid cells (ILCs) and their role in immunological disorders (an update). Cell Immunol. 2015;298:66-76.
98. Reader JR, Hyde DM, Schelegle ES, Aldrich MC, Stoddard AM, McLane MP, et al. Interleukin-9 induces mucous cell metaplasia independent of inflammation. Am J Respir Cell Mol Biol. 2003;28:664-72.
99. Levitt RC, McLane MP, MacDonald D, Ferrante V, Weiss C, Zhou T, et al. IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. J Allergy Clin Immunol. 1999;103:S485-91.
100. Kung TT, Luo B, Crawley Y, Garlisi CG, Devito K, Minnicozzi M, et al. Effect of anti-mIL-9 antibody on the development of pulmonary inflammation and airway hyperresponsiveness in allergic mice. Am J Respir Cell Mol Biol. 2001;25:600-5.
101. Cheng G, Arima M, Honda K, Hirata H, Eda F, Yoshida N, et al. Anti-Interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med. 2002;166:409-16.
102. Temann U-A, Geba GP, Rankin JA, Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med. 1998;188:1307-20.
103. Louahed J, Zhou Y, Maloy WL, Rani PU, Weiss C, Tomer Y, et al. Interleukin 9 promotes influx and local maturation of eosinophils. Blood. 2001;97:1035-42.
104. Louahed J, Toda M, Jen J, Hamid Q, Renauld J-C, Levitt RC, et al. Interleukin-9 upregulates mucus expression in the airways. Am J Respir Cell Mol Biol. 2000;22:649-56.
105. Dong Q, Louahed J, Vink A, Sullivan CD, Messler CJ, Zhou Y, et al. IL-9 induces chemokine expression in lung epithelial cells and baseline airway eosinophilia in transgenic mice. Eur J Immunol. 1999;29:2130-9.
106. Baraldo S, Faffe DS, Moore PE, Whitehead T, McKenna M, Silverman ES, et al. Interleukin-9 influences chemokine release in airway smooth muscle: role of ERK. Am J Physiol Lung Cell Mol Physiol. 2003;284:L1093-102.
107. Eklund KK, Ghildyal N, Austen KF, Stevens RL. Induction by IL-9 and suppression by IL-3 and IL-4 of the levels of chromosome 14-derived transcripts that encode late-expressed mouse mast cell proteases. J Immunol. 1993;151:4266-73.
108. Kearley J, Erjefalt JS, Andersson C, Benjamin E, Jones CP, Robichaud A, et al. IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med. 2011;183:865-75.
109. Vink A, Warnier G, Brombacher F, Renauld J-C. Interleukin 9- induced in vivo expansion of the B-1 lymphocyte population. J
Exp Med. 1999;189:1413-23.
110. Petit-Frere C, Dugas B, Braquet P, Mencia-Huerta J. Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes. Immunology. 1993;79:146.
111. Osterfeld H, Ahrens R, Strait R, Finkelman FD, Renauld J-C, Hogan SP. Differential roles for the IL-9/IL-9 receptor -chain pathway in systemic and oral antigen-induced anaphylaxis. J Allergy Clin Immunol. 2010;125:469-76.
112. Ciprandi G. Serum interleukin 9 in allergic rhinitis. Ann Allergy Asthma Immunol. 2010;104:180-1.
113. Ma L, Xue HB, Guan XH, Shu CM, Zhang JH, Yu J. Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis. Clin Exp Immunol. 2014;175:25-31.
114. Mackay IR, Rosen FS, Kamradt T, Mitchison NA. Tolerance and autoimmunity. New Engl J Med. 2001;344:655-64.
115. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S. Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis. J Rheumatol. 2011;38:2193-7.
116. Ouyang H, Shi Y, Liu Z, Feng S, Li L, Su N, et al. Increased interleukin-9 and CD4+ IL-9+ T cells in patients with systemic lupus erythematosus. Mol Med Rep. 2013;7:1031-7.
117. Singh TP, Schön MP, Wallbrecht K, Gruber-Wackernagel A, Wang X-J, Wolf P. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLOS ONE. 2013;8:e51752.
118. Ben-Nun A, Wekerle H, Cohen IR. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol. 1981;11:195-9.
119. Conforti L, Gilley J, Coleman MP. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat Rev Neurosci. 2014;15:394-409.
120. Li H, Nourbakhsh B, Ciric B, Zhang GX, Rostami A. Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population. J Immunol. 2010;185:4095-100.
121. Kara EE, Comerford I, Bastow CR, Fenix KA, Litchfield W, Handel TM, et al. Distinct chemokine receptor axes regulate Th9 cell trafficking to allergic and autoimmune inflammatory sites. J Immunol. 2013;191:1110-7.
122. Zhou Y, Sonobe Y, Akahori T, Jin S, Kawanokuchi J, Noda M, et al. IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol. 2011;186:4415-21.
123. Yang J, Li Q, Yang X, Li M. Interleukin-9 is associated with elevated anti-double-stranded DNA antibodies in lupus-prone mice. Mol Med. 2015;21:364-70.
124. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. New Engl J Med. 2003;349:1526-33.
125. Crispín JC, Tsokos GC. Interleukin-17-producing T cells in lupus. Curr Opin Rheumatol. 2010;22:499-503.
126. Dantas AT, Marques CDL, da Rocha Junior LF, Cavalcanti MB, Gonc¸alves SMC, Cardoso PRG, et al. Increased serum interleukin-9 levels in rheumatoid arthritis and systemic lupus erythematosus: pathogenic role or just an epiphenomenon? Dis Markers. 2015;2015:519638.
127. Cheng F, Guo Z, Xu H, Yan D, Li Q. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis. 2009;68:604-6.
128. van Vollenhoven RF. Rheumatoid arthritis in 2012: progress in RA genetics, pathology and therapy. Nat Rev Rheumatol.
2013;9:70-2.
129. Ciccia F, Guggino G, Rizzo A, Manzo A, Vitolo B, La Manna MP, et al. Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2015;54:2264-72.
130. Yang J, Yang X, Zou H, Chu Y, Li M. Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatology (Oxford). 2011;50:1366-72.
131. Schlapbach C, Gehad A, Yang C, Watanabe R, Guenova E, Teague JE, et al. Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. Sci Transl Med. 2014;6:219ra8.
132. Jia L, Wu C. Differentiation, regulation and function of th9 cells. T helper cell differentiation and their function. Springer; 2014. p. 181-207.
133. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med. 2009;15:199-207.
134. Fuss IJ, Neurath M, Boirivant M, Klein JS, De La Motte C, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261-70.
135. Nalleweg N, Chiriac MT, Podstawa E, Lehmann C, Rau TT, Atreya R, et al. IL-9 and its receptor are predominantly involved in the pathogenesis of UC. Gut. 2015;64:743-55.
136. Mudter J, Yu J, Zufferey C, Brüstle A, Wirtz S, Weigmann B, et al. IRF4 regulates IL-17A promoter activity and controls RORt-dependent Th17 colitis in vivo. Inflamm Bowel Dis. 2011;17:1343-58.
137. Gerlach K, Hwang Y, Nikolaev A, Atreya R, Dornhoff H, Steiner S, et al. TH9 cells that express the transcription factor PU. 1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. 2014;15:676-86.
138. Gerlach K, McKenzie AN, Neurath MF, Weigmann B. IL-9 regulates intestinal barrier function in experimental T cell mediated colitis. Tissue Barriers. 2015;3:e983777.
139. Licona-Limón P, Henao-Mejia J, Temann AU, Gagliani N, Licona-Limón I, Ishigame H, et al. Th9 cells drive host immunity against gastrointestinal worm infection. Immunity. 2013;39:744-57.
140. Turner J-E, Morrison PJ, Wilhelm C, Wilson M, Ahlfors H, Renauld J-C, et al. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in Helminth-induced lung inflammation. J Exp Med. 2013;210:2951-65.
141. Pang N, Zhang F, Ma X, Zhang Z, Zhao H, Xin Y, et al. Th9/IL-9 profile in human echinococcosis: their involvement in immune response during infection by Echinococcus granulosus. Mediat Inflamm. 2014;2014:781649.
142. Khan W, Richard M, Akiho H, Blennerhasset P, Humphreys N, Grencis R, et al. Modulation of intestinal muscle contraction by interleukin-9 (IL-9) or IL-9 neutralization: correlation with worm expulsion in murine nematode infections. Infect Immun. 2003;71:2430-8.
143. Faulkner H, Renauld J-C, Van Snick J, Grencis R. Interleukin9 enhances resistance to the intestinal nematode Trichuris muris. Infect Immun. 1998;66:3832-40.
144. Richard M, Grencis RK, Humphreys NE, Renauld J-C, Van Snick J. Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc Natl Acad Sci U S A. 2000;97:767-72.
145. Anuradha R, George PJ, Hanna LE, Chandrasekaran V, Kumaran P, Nutman TB, et al. IL-4-, TGF--, and IL-1-dependent expansion of parasite antigen-specific Th9 cells is associated with clinical pathology in human lymphatic filariasis. J Immunol. 2013;191:2466-73.
146. Anuradha R, Munisankar S, Bhootra Y, Jagannathan J, Dolla C, Kumaran P, et al. IL-10- and TGFbeta-mediated Th9 responses in a human Helminth infection. PLoS Negl Trop Dis. 2016;10:e0004317.
147. Wu B, Huang C, Kato-Maeda M, Hopewell PC, Daley CL, Krensky AM, et al. IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. Clin Immunol. 2008;126:202-10.
148. Grohmann U, Van Snick J, Campanile F, Silla S, Giampietri A, Vacca C, et al. IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-, IL-12, and IFN-, and induction of IL-10. J Immunol. 2000;164:4197-203.
149. Pilette C, Ouadrhiri Y, Van Snick J, Renauld J-C, Staquet P, Vaerman J-P, et al. IL-9 inhibits oxidative burst and TNF- release in lipopolysaccharide-stimulated human monocytes through TGF-. J Immunol. 2002;168:4103-11.
150. Yang XR, Pfeiffer RM, Wheeler W, Yeager M, Chanock S, Tucker MA, et al. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. Int J Cancer. 2009;125:2912-7.
151. Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, et al. Robust tumor immunity to melanoma mediated by interleukin-9 producing T cells. Nat Med. 2012;18: 1248-53.
152. Fang Y, Chen X, Bai Q, Qin C, Mohamud AO, Zhu Z, et al. IL-9 inhibits HTB-72 melanoma cell growth through upregulation of p21 and TRAIL. J Surg Oncol. 2015;111:969-74.
153. Abdul-Wahid A, Cydzik M, Prodeus A, Alwash M, Stanojcic M, Thompson M, et al. Induction of antigen-specific TH 9 immunity accompanied by mast cell activation blocks tumor cell engraftment. Int J Cancer. 2016;139:841-53.
154. Lu Y, Hong S, Li H, Park J, Hong B, Wang L, et al. Th9 cells promote antitumor immune responses in vivo. J Clin Invest. 2012;122:4160.
155. Park J, Li H, Zhang M, Lu Y, Hong B, Zheng Y, et al. Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy. Cancer Immunol Immunother. 2014;63:835-45.
156. Miao B-P, Zhang R-S, Sun H-J, Yu Y-P, Chen T, Li L-J, et al. Inhibition of squamous cancer growth in a mouse model by Staphylococcal enterotoxin B-triggered Th9 cell expansion. Cell Mol Immunol. 2017;14:371-9.
157. Merz H, Houssiau F, Orscheschek K, Renauld J-C, Fliedner A, Herin M, et al. Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin’s disease and large cell anaplastic lymphoma. Blood. 1991;78:1311-7.
158. Tan H, Wang S, Zhao L. A tumour-promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways. Clin Exp Pharmacol Physiol. 2017;44:213-21.
159. Lange K, Uckert W, Blankenstein T, Nadrowitz R, Bittner C, Renauld J-C, et al. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene. 2003;22:517-27.
160. Simonovic SZ, Mihaljevic O, Majstorovic I, Djurdjevic P, Kostic I, Djordjevic OM, et al. Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer: elevated Th2/Th9 cytokine production before and reduced Th2 cytokine production after radioactive iodine therapy. Cancer Immunol Immunother. 2015;64:75-82.
161. Vink A, Renauld JC, Warnier G, Van Snick J. Interleukin-9 stimulates in vitro growth of mouse thymic lymphomas. Eur J Immunol. 1993;23:1134-8.
162. Chen N, Lu K, Li P, Lv X, Wang X. Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia. Int J Clin Exp Pathol. 2014;7:2319.
163. Smith SE, Hoelzinger DB, Dominguez AL, Van Snick J, Lustgarten J. Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunol Immunother. 2011;60:1775-87.
164. Ganjalikhani-Hakemi M, Yazdani R, Sherkat R, Homayouni V, Masjedi M, Hosseini M. Evaluation of the T helper 17 cell-specific genes and the innate lymphoid cells counts in the peripheral blood of patients with the common variable immunodeficiency. J Res Med Sci. 2014;19 Suppl. 1:S30-5.
165. Azizi G, Rezaei N, Kiaee F, Tavakolinia N, Yazdani R, Mirshafiey A, et al. T-cell abnormalities in common variable immunodeficiency. J Investig Allergol Clin Immunol. 2016;4: 233-43.
166. Yazdani R, Fatholahi M, Ganjalikhani-Hakemi M, Abolhassani H, Azizi G, Hamid KM, et al. Role of apoptosis in common variable immunodeficiency and selective immunoglobulin A deficiency. Mol Immunol. 2016;71:1-9.
167. Yazdani R, Ganjalikhani-Hakemi M, Esmaeili M, Abolhassani H, Vaeli S, Rezaei A, et al. Impaired Akt phosphorylation in B-cells of patients with common variable immunodeficiency. Clin Immunol. 2017;175:124-32.
168. Azizi G, Ahmadi M, Abolhassani H, Yazdani R, Mohammadi H, Mirshafiey A, et al. Autoimmunity in primary antibody deficiencies. Int Arch Allergy Immunol. 2016;171:180-93.
169. Azizi G, Abolhassani H, Asgardoon MH, Alinia T, Yazdani R, Mohammadi J, et al. Autoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management. Expert Rev Clin Immunol. 2017;13:101-15.
170. Yazdani R, Latif A, Tabassomi F, Abolhassani H, Azizi G, Rezaei N, et al. Clinical phenotype classification for selective immunoglobulin A deficiency. Expert Rev Clin Immunol. 2015;11:1245-54.
171. Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol. 2012;30:3396-401.
172. Végran F, Apetoh L, Ghiringhelli F. Th9 cells: a novel CD4 Tcell subset in the immune war against cancer. Cancer Res. 2015;75:475-9.
173. Zhou Y, McLane M, Levitt RC. Th2 cytokines and asthma-interleukin-9 as a therapeutic target for asthma. Respir Res. 2001;2:80.
174. Barnes PJ. Cytokine modulators as novel therapies for asthma. Annu Rev Pharmacol Toxicol. 2002;42:81-98.
175. Jabeen R, Kaplan MH. The symphony of the ninth: the development and function of Th9 cells. Curr Opin Immunol. 2012;24:303-7.
176. Uyttenhove C, Simpson RJ, Van Snick J. Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci U S A. 1988;85:6934-8.
177. Townsend MJ, Fallon PG, Matthews DJ, Smith P, Jolin HE, McKenzie AN. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity. 2000;13:573-83.
178. Matsuzawa S, Sakashita K, Kinoshita T, Ito S, Yamashita T, Koike K. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol. 2003;170:3461-7.
179. Fujiki H, Kimura T, Minamiguchi H, Harada S, Wang J, Nakao M, et al. Role of human interleukin-9 as a megakaryocyte potentiator in culture. Exp Hematol. 2002;30:1373-80.
180. Gounni AS, Hamid Q, Rahman SM, Hoeck J, Yang J, Shan L. IL-9-mediated induction of eotaxin1/CCL11 in human airway smooth muscle cells. J Immunol. 2004;173:2771-9.
181. Dardalhon V, Collins M, Kuchroo VK. Physical attraction of Th9 cells is skin deep. Ann Transl Med. 2015;3:74.
182. Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC, et al. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol. 2000;105:108-15.
2. Yamane H, Paul WE. Early signaling events that underlie fate decisions of naive CD4(+) T cells toward distinct T-helper cell subsets. Immunol Rev. 2013;252:12-23.
3. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, et al. Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol. 2008;9: 1341-6.
4. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(−) effector T cells. Nat Immunol. 2008;9:1347-55.
5. Schmitt E, Van Brandwijk R, Van Snick J, Siebold B, Rude E. TCGF III/P40 is produced by naive murine CD4+ T cells but is not a general T cell growth factor. Eur J Immunol. 1989;19:2167-70.
6. Schmitt E, Germann T, Goedert S, Hoehn P, Huels C, Koelsch S, et al. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGFbeta and IL-4, and is inhibited by IFN-gamma. J Immunol. 1994;153:3989-96.
7. Stassen M, Schmitt E, Bopp T. From interleukin-9 to T helper 9 cells. Ann N Y Acad Sci. 2012;1247:56-68.
8. Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol. 2010;10:683-7.
9. Hültner L, Druez C, Moeller J, Uyttenhove C, Schmitt E, Rüde E, et al. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol. 1990;2:1413-6.
10. Mock BA, Krall M, Kozak CA, Nesbitt MN, McBride OW, Renauld JC, et al. IL9 maps to mouse chromosome 13 and human chromosome 5. Immunogenetics. 1990;31:265-70.
11. Renauld J-C, Goethals A, Houssiau F, Merz H, Van Roost E, Van Snick J. Human P40/IL-9. Expression in activated CD4+ T cells, genomic organization, and comparison with the mouse gene. J Immunol. 1990;144:4235-41.
12. Renauld JC, Druez C, Kermouni A, Houssiau F, Uyttenhove C, Van Roost E, et al. Expression cloning of the murine and human interleukin 9 receptor cDNAs. Proc Natl Acad Sci U S A. 1992;89:5690-4.
13. Idzerda RL, March CJ, Mosley B, Lyman SD, Bos TV, Gimpel SD, et al. Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J Exp Med. 1990;171:861-73.
14. Druez C, Coulie P, Uyttenhove C, Van Snick J. Functional and biochemical characterization of mouse P40/IL-9 receptors. J Immunol. 1990;145:2494-9.
15. Cosmi L, Liotta F, Angeli R, Mazzinghi B, Santarlasci V, Manetti R, et al. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood. 2004;103:3117-21.
16. Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, Schreiner B, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med. 2009;206:1653-60.
17. Fawaz LM, Sharif-Askari E, Hajoui O, Soussi-Gounni A, Hamid Q, Mazer BD. Expression of IL-9 receptor alpha chain on human germinal center B cells modulates IgE secretion. J Allergy Clin Immunol. 2007;120:1208-15.
18. Goswami R, Kaplan MH. A brief history of IL-9. J Immunol. 2011;186:3283-8.
19. Demoulin J-B, Uyttenhove C, Van Roost E, DeLestré B, Donckers D, Van Snick J, et al. A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9. Mol Cell Biol. 1996;16: 4710-6.
20. Demoulin JB, Van Roost E, Stevens M, Groner B, Renauld JC. Distinct roles for STAT1, STAT3, and STAT5 in differentiation gene induction and apoptosis inhibition by interleukin-9. J Biol Chem. 1999;274:25855-61.
21. Yin T, Keller SR, Quelle FW, Witthuhn BA, Tsang ML-S, Lienhard GE, et al. Interleukin-9 induces tyrosine phosphorylation of insulin receptor substrate-1 via JAK tyrosine kinases. J Biol Chem. 1995;270:20497-502.
22. Demoulin J-B, Louahed J, Dumoutier L, Stevens M, Renauld JC. MAP kinase activation by interleukin-9 in lymphoid and mast cell lines. Oncogene. 2003;22:1763-70.
23. Gessner A, Blum H, Röllinghoff M. Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice. Immunobiology. 1993;189:419-35.
24. Dugas B, Renauld JC, Pène J, Bonnefoy JY, Peti-Frère C, Braquet P, et al. Interleukin-9 potentiates the interleukin-4- induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes. Eur J Immunol. 1993;23:1687-92.
25. Lu L-F, Lind EF, Gondek DC, Bennett KA, Gleeson MW, PinoLagos K, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature. 2006;442:997-1002.
26. Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola J, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A. 2009;106:12885-90.
27. Beriou G, Bradshaw EM, Lozano E, Costantino CM, Hastings WD, Orban T, et al. TGF-beta induces IL-9 production from human Th17 cells. J Immunol. 2010;185:46-54.
28. Putheti P, Awasthi A, Popoola J, Gao W, Strom TB. Human CD4 memory T cells can become CD4 IL-9+ T cells. PLoS ONE. 2010;5:e8706.
29. Beriou G, Bradshaw EM, Lozano E, Costantino CM, Hastings WD, Orban T, et al. TGF- induces IL-9 production from human Th17 cells. J Immunol. 2010;185:46-54.
30. Wong MT, Ye JJ, Alonso MN, Landrigan A, Cheung RK, Engleman E, et al. Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol cell Biol. 2010;88:624-31.
31. Jones TG, Hallgren J, Humbles A, Burwell T, Finkelman FD, Alcaide P, et al. Antigen-induced increases in pulmonary mast cell progenitor numbers depend on IL-9 and CD1d-restricted NKT cells. J Immunol. 2009;183:5251-60.
32. Lauwerys BR, Garot N, Renauld J-C, Houssiau FA. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol. 2000;165:1847-53.
33. Farahani R, Sherkat R, Hakemi MG, Eskandari N, Yazdani R. Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma. Adv Biomed Res. 2014;3:127.
34. Stassen M, Müller C, Arnold M, Hültner L, Klein-Hessling S, Neudörfl C, et al. IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-B is decisively involved in the expression of IL-9. J Immunol. 2001;166:4391-8.
35. Stassen M, Arnold M, Hültner L, Müller C, Neudörfl C, Reineke T, et al. Murine bone marrow-derived mast cells as potent producers of IL-9: costimulatory function of IL-10 and kit ligand in the presence of IL-1. J Immunol. 2000;164:5549-55.
36. Hültner L, Kölsch S, Stassen M, Kaspers U, Kremer J-P, Mailhammer R, et al. Inactivated mast cells, IL-1 up-regulates the production of several Th2-related cytokines including IL-9. J Immunol. 2000;164:5556-63.
37. Wiener Z, Falus A, Toth S. IL-9 increases the expression of several cytokines in activated mast cells, while the IL-9-induced IL-9 production is inhibited in mast cells of histamine-free transgenic mice. Cytokine. 2004;26:122-30.
38. Wilhelm C, Hirota K, Stieglitz B, Van Snick J, Tolaini M, Lahl K, et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol. 2011;12:1071-7.
39. Sugimoto T, Ishikawa Y, Yoshimoto T, Hayashi N, Fujimoto J, Nakanishi K. Interleukin 18 acts on memory T helper cells type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse. J Exp Med. 2004;199:535-45.
40. Hayashi N, Yoshimoto T, Izuhara K, Matsui K, Tanaka T, Nakanishi K. T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN- and IL-13 production. Proc Natl Acad Sci U S A. 2007;104:14765-70.
41. Gloghini A, Bongarzone I, editors. Cell-secreted signals shape lymphoma identity. Semin Cancer Biol. 2015;34:81-91.
42. Mahnke YD, Beddall MH, Roederer M. OMIP-017: human CD4+ helper T-cell subsets including follicular helper cells. Cytometry A. 2013;83:439-40.
43. Keating P, Munim A, Hartmann JX. Effect of vitamin D on T-helper type 9 polarized human memory cells in chronic persistent asthma. Ann Allergy Asthma Immunol. 2014;112:154-62.
44. Ye Z-J, Yuan M-L, Zhou Q, Du R-H, Yang W-B, Xiong X-Z, et al. Differentiation and recruitment of Th9 cells stimulated by pleural mesothelial cells in human Mycobacterium tuberculosis infection. PLoS ONE. 2012;7:e31710.
45. Ye Z-J, Zhou Q, Yin W, Yuan M-L, Yang W-B, Xiong X-Z, et al. Differentiation and immune regulation of IL-9− producing CD4+ T cells in malignant pleural effusion. Am J Respir Crit Care Med. 2012;186:1168-79.
46. Tan C, Gery I. The unique features of Th9 cells and their products. Crit Rev Immunol. 2012;32:1-10.
47. Tan C, Aziz MK, Lovaas JD, Vistica BP, Shi G, Wawrousek EF, et al. Antigen-specific Th9 cells exhibit uniqueness in their kinetics of cytokine production and short retention at the inflammatory site. J Immunol. 2010;185:6795-801.
48. Jäger A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol. 2009;183:7169-77.
49. Végran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, et al. The transcription factor IRF1 dictates the IL-21- dependent anticancer functions of TH9 cells. Nat Immunol. 2014;15:758-66.
50. Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531-64.
51. Murugaiyan G, Beynon V, Da Cunha AP, Joller N, Weiner HL. IFN- limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J Immunol. 2012;189:5277-83.
52. Liao W, Spolski R, Li P, Du N, West EE, Ren M, et al. Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc Natl Acad Sci U S A. 2014;111:3508-13.
53. Angkasekwinai P, Chang SH, Thapa M, Watarai H, Dong C. Regulation of IL-9 expression by IL-25 signaling. Nat Immunol. 2010;11:250-6.
54. Pan H-F, Leng R-X, Li X-P, Zheng SG, Ye D-Q. Targeting T-helper 9 cells and interleukin-9 in autoimmune diseases. Cytokine Growth Factor Rev. 2013;24:515-22.
55. Uyttenhove C, Brombacher F, Van Snick J. TGF- interactions with IL-1 family members trigger IL-4-independent IL-9 production by mouse CD4+ T cells. Eur J Immunol. 2010;40:2230-5.
56. Yao W, Zhang Y, Jabeen R, Nguyen ET, Wilkes DS, Tepper RS, et al. Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP. Immunity. 2013;38:360-72.
57. Kaplan MH, Hufford MM, Olson MR. The development and in vivo function of T helper 9 cells. Nat Rev Immunol. 2015;15:295-307.
58. Jones CP, Gregory LG, Causton B, Campbell GA, Lloyd CM. Activin A and TGF- promote T H 9 cell-mediated pulmonary allergic pathology. J Allergy Clin Immunol. 2012;129:1000-10.
59. Richard AC, Tan C, Hawley ET, Gomez-Rodriguez J, Goswami R, Yang X-P, et al. The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells. J Immunol. 2015;194:3567-82.
60. Zhao P, Xiao X, Ghobrial RM, Li XC. IL-9 and Th9 cells: progress and challenges. Int Immunol. 2013;25:547-51.
61. Xiao X, Balasubramanian S, Liu W, Chu X, Wang H, Taparowsky EJ, et al. OX40 signaling favors the induction of TH9 cells and airway inflammation. Nat Immunol. 2012;13:981-90.
62. Tone M, Tone Y, Adams E, Yates SF, Frewin MR, Cobbold SP, et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A. 2003;100:15059-64.
63. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol. 2003;3:609-20.
64. Xiao X, Shi X, Fan Y, Zhang X, Wu M, Lan P, et al. GITR subverts Foxp3(+) Tregs to boost Th9 immunity through regulation of histone acetylation. Nat Commun. 2015;6:8266.
65. Kim I-K, Kim B-S, Koh C-H, Seok J-W, Park J-S, Shin K-S, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein co stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. Nat Med. 2015;21:1010-7.
66. Amsen D, Antov A, Flavell RA. The different faces of Notch in Thelper-cell differentiation. Nat Rev Immunol. 2009;9:116-24.
67. Elyaman W, Bassil R, Bradshaw EM, Orent W, Lahoud Y, Zhu B, et al. Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity. 2012;36:623-34.
68. Kerzerho J, Maazi H, Speak AO, Szely N, Lombardi V, Khoo B, et al. Programmed cell death ligand 2 regulates T H 9 differentiation and induction of chronic airway hyperreactivity. J Allergy Clin Immunol. 2013;131:1048-57.
69. Li H, Edin ML, Bradbury JA, Graves JP, DeGraff LM, Gruzdev A, et al. Cyclooxygenase-2 inhibits T helper cell type 9 differentiation during allergic lung inflammation via down-regulation of IL-17RB. Am J Respir Crit Care Med. 2013;187:812-22.
70. Chang H-C, Sehra S, Goswami R, Yao W, Yu Q, Stritesky GL, et al. The transcription factor PU. 1 is required for the development of IL-9 producing T cells and allergic inflammation. Nat Immunol. 2010;11:527-34.
71. Ramming A, Druzd D, Leipe J, Schulze-Koops H, Skapenko A. Maturation-related histone modifications in the PU.1 promoter regulate Th9-cell development. Blood. 2012;119:4665-74.
72. Koh B, Hufford MM, Pham D, Olson MR, Wu T, Jabeen R, et al. The ETS family transcription factors Etv5 and PU.1 function in parallel to promote Th9 cell development. J Immunol. 2016;197:2465-72.
73. Goswami R, Jabeen R, Yagi R, Pham D, Zhu J, Goenka S, et al. STAT6-dependent regulation of Th9 development. J Immunol. 2012;188:968-75.
74. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996;4:313-9.
75. Staudt V, Bothur E, Klein M, Lingnau K, Reuter S, Grebe N, et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity. 2010;33: 192-202.
76. Maruyama T, Li J, Vaque JP, Konkel JE, Wang W, Zhang B, et al. Control of the differentiation of regulatory T cells and TH17 cells by the DNA-binding inhibitor Id3. Nat Immunol. 2011;12:86-95.
77. Nakatsukasa H, Zhang D, Maruyama T, Chen H, Cui K, Ishikawa M, et al. The DNA-binding inhibitor Id3 regulates IL-9 production in CD4+ T cells. Nat Immunol. 2015;16:1077-84.
78. Deng Y, Wang Z, Chang C, Lu L, Lau CS, Lu Q. Th9 cells and IL-9 in autoimmune disorders: pathogenesis and therapeutic potentials. Hum Immunol. 2017;78:120-8.
79. Bassil R, Orent W, Olah M, Kurdi AT, Frangieh M, Buttrick T, et al. BCL6 controls Th9 cell development by repressing Il9 transcription. J Immunol. 2014;193:198-207.
80. Hermann-Kleiter N, Baier G. NFAT pulls the strings during CD4+ T helper cell effector functions. Blood. 2010;115:2989-97.
81. Perumal NB, Kaplan MH. Regulating Il9 transcription in T helper cells. Trends Immunol. 2011;32:146-50.
82. Jash A, Sahoo A, Kim G-C, Chae C-S, Hwang J-S, Kim J-E, et al. Nuclear factor of activated T cells 1 (NFAT1)-induced permissive chromatin modification facilitates nuclear factor-B (NF-B)-mediated interleukin-9 (IL-9) transactivation. J Biol Chem. 2012;287:15445-57.
83. Kadereit S, Mohammad SF, Miller RE, Woods KD, Listrom CD, McKinnon K, et al. Reduced NFAT1 protein expression in human umbilical cord blood T lymphocytes. Blood. 1999;94:3101-7.
84. Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, Wang X-F. Targeted disruption of Smad3 reveals an essential role in transforming growth factor -mediated signaltransduction. Mol Cell Biol. 1999;19:2495-504.
85. Tamiya T, Ichiyama K, Kotani H, Fukaya T, Sekiya T, Shichita T, et al. Smad2/3 and IRF4 play a cooperative role in IL-9- producing T cell induction. J Immunol. 2013;191:2360-71.
86. Kaplan MH. Th9 cells: differentiation and disease. Immunol Rev. 2013;252:104-15.
87. Wang A, Pan D, Lee Y-H, Martinez GJ, Feng X-H, Dong C. Cutting edge: Smad2 and Smad4 Regulate TGF--mediated Il9 gene expression via EZH2 displacement. J Immunol. 2013;191:4908-12.
88. Jabeen R, Goswami R, Awe O, Kulkarni A, Nguyen ET, Attenasio A, et al. Th9 cell development requires a BATF-regulated transcriptional network. J Clin Invest. 2013;123:4641.
89. Echlin DR, Tae H-J, Mitin N, Taparowsky EJ. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos. Oncogene. 2000;19:1752-63.
90. Vegran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, et al. The transcription factor IRF1 dictates the IL-21- dependent anticancer functions of TH9 cells. Nat Immunol. 2014;15:758-66.
91. Yang H, Bi Y, Xue L, Wang J, Lu Y, Zhang Z, et al. Multifaceted modulation of SIRT1 in cancer and inflammation. Crit Rev Oncog. 2015;20:49-64.
92. Wang Y, Bi Y, Chen X, Li C, Li Y, Zhang Z, et al. Histone deacetylase SIRT1 negatively regulates the differentiation of interleukin-9-producing CD4+ T cells. Immunity. 2016;44:1337-49.
93. Berg LJ, Finkelstein LD, Lucas JA, Schwartzberg PL. Tec family kinases in T lymphocyte development and function. Annu Rev Immunol. 2005;23:549-600.
94. Gomez-Rodriguez J, Meylan F, Handon R, Hayes ET, Anderson SM, Kirby MR, et al. Itk is required for Th9 differentiation via TCR-mediated induction of IL-2 and IRF4. Nat Commun. 2016:7.
95. Kim HY, DeKruyff RH, Umetsu DT. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat
Immunol. 2010;11:577---84.
96. Yu S, Kim HY, Chang Y-J, DeKruyff RH, Umetsu DT. Innate lymphoid cells and asthma. J Allergy Clin Immunol. 2014;133:943-50.
97. Yazdani R, Sharifi M, Shirvan AS, Azizi G, Ganjalikhani-Hakemi M. Characteristics of innate lymphoid cells (ILCs) and their role in immunological disorders (an update). Cell Immunol. 2015;298:66-76.
98. Reader JR, Hyde DM, Schelegle ES, Aldrich MC, Stoddard AM, McLane MP, et al. Interleukin-9 induces mucous cell metaplasia independent of inflammation. Am J Respir Cell Mol Biol. 2003;28:664-72.
99. Levitt RC, McLane MP, MacDonald D, Ferrante V, Weiss C, Zhou T, et al. IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. J Allergy Clin Immunol. 1999;103:S485-91.
100. Kung TT, Luo B, Crawley Y, Garlisi CG, Devito K, Minnicozzi M, et al. Effect of anti-mIL-9 antibody on the development of pulmonary inflammation and airway hyperresponsiveness in allergic mice. Am J Respir Cell Mol Biol. 2001;25:600-5.
101. Cheng G, Arima M, Honda K, Hirata H, Eda F, Yoshida N, et al. Anti-Interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med. 2002;166:409-16.
102. Temann U-A, Geba GP, Rankin JA, Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med. 1998;188:1307-20.
103. Louahed J, Zhou Y, Maloy WL, Rani PU, Weiss C, Tomer Y, et al. Interleukin 9 promotes influx and local maturation of eosinophils. Blood. 2001;97:1035-42.
104. Louahed J, Toda M, Jen J, Hamid Q, Renauld J-C, Levitt RC, et al. Interleukin-9 upregulates mucus expression in the airways. Am J Respir Cell Mol Biol. 2000;22:649-56.
105. Dong Q, Louahed J, Vink A, Sullivan CD, Messler CJ, Zhou Y, et al. IL-9 induces chemokine expression in lung epithelial cells and baseline airway eosinophilia in transgenic mice. Eur J Immunol. 1999;29:2130-9.
106. Baraldo S, Faffe DS, Moore PE, Whitehead T, McKenna M, Silverman ES, et al. Interleukin-9 influences chemokine release in airway smooth muscle: role of ERK. Am J Physiol Lung Cell Mol Physiol. 2003;284:L1093-102.
107. Eklund KK, Ghildyal N, Austen KF, Stevens RL. Induction by IL-9 and suppression by IL-3 and IL-4 of the levels of chromosome 14-derived transcripts that encode late-expressed mouse mast cell proteases. J Immunol. 1993;151:4266-73.
108. Kearley J, Erjefalt JS, Andersson C, Benjamin E, Jones CP, Robichaud A, et al. IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med. 2011;183:865-75.
109. Vink A, Warnier G, Brombacher F, Renauld J-C. Interleukin 9- induced in vivo expansion of the B-1 lymphocyte population. J
Exp Med. 1999;189:1413-23.
110. Petit-Frere C, Dugas B, Braquet P, Mencia-Huerta J. Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes. Immunology. 1993;79:146.
111. Osterfeld H, Ahrens R, Strait R, Finkelman FD, Renauld J-C, Hogan SP. Differential roles for the IL-9/IL-9 receptor -chain pathway in systemic and oral antigen-induced anaphylaxis. J Allergy Clin Immunol. 2010;125:469-76.
112. Ciprandi G. Serum interleukin 9 in allergic rhinitis. Ann Allergy Asthma Immunol. 2010;104:180-1.
113. Ma L, Xue HB, Guan XH, Shu CM, Zhang JH, Yu J. Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis. Clin Exp Immunol. 2014;175:25-31.
114. Mackay IR, Rosen FS, Kamradt T, Mitchison NA. Tolerance and autoimmunity. New Engl J Med. 2001;344:655-64.
115. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S. Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis. J Rheumatol. 2011;38:2193-7.
116. Ouyang H, Shi Y, Liu Z, Feng S, Li L, Su N, et al. Increased interleukin-9 and CD4+ IL-9+ T cells in patients with systemic lupus erythematosus. Mol Med Rep. 2013;7:1031-7.
117. Singh TP, Schön MP, Wallbrecht K, Gruber-Wackernagel A, Wang X-J, Wolf P. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLOS ONE. 2013;8:e51752.
118. Ben-Nun A, Wekerle H, Cohen IR. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol. 1981;11:195-9.
119. Conforti L, Gilley J, Coleman MP. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat Rev Neurosci. 2014;15:394-409.
120. Li H, Nourbakhsh B, Ciric B, Zhang GX, Rostami A. Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population. J Immunol. 2010;185:4095-100.
121. Kara EE, Comerford I, Bastow CR, Fenix KA, Litchfield W, Handel TM, et al. Distinct chemokine receptor axes regulate Th9 cell trafficking to allergic and autoimmune inflammatory sites. J Immunol. 2013;191:1110-7.
122. Zhou Y, Sonobe Y, Akahori T, Jin S, Kawanokuchi J, Noda M, et al. IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol. 2011;186:4415-21.
123. Yang J, Li Q, Yang X, Li M. Interleukin-9 is associated with elevated anti-double-stranded DNA antibodies in lupus-prone mice. Mol Med. 2015;21:364-70.
124. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. New Engl J Med. 2003;349:1526-33.
125. Crispín JC, Tsokos GC. Interleukin-17-producing T cells in lupus. Curr Opin Rheumatol. 2010;22:499-503.
126. Dantas AT, Marques CDL, da Rocha Junior LF, Cavalcanti MB, Gonc¸alves SMC, Cardoso PRG, et al. Increased serum interleukin-9 levels in rheumatoid arthritis and systemic lupus erythematosus: pathogenic role or just an epiphenomenon? Dis Markers. 2015;2015:519638.
127. Cheng F, Guo Z, Xu H, Yan D, Li Q. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis. 2009;68:604-6.
128. van Vollenhoven RF. Rheumatoid arthritis in 2012: progress in RA genetics, pathology and therapy. Nat Rev Rheumatol.
2013;9:70-2.
129. Ciccia F, Guggino G, Rizzo A, Manzo A, Vitolo B, La Manna MP, et al. Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2015;54:2264-72.
130. Yang J, Yang X, Zou H, Chu Y, Li M. Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatology (Oxford). 2011;50:1366-72.
131. Schlapbach C, Gehad A, Yang C, Watanabe R, Guenova E, Teague JE, et al. Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. Sci Transl Med. 2014;6:219ra8.
132. Jia L, Wu C. Differentiation, regulation and function of th9 cells. T helper cell differentiation and their function. Springer; 2014. p. 181-207.
133. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med. 2009;15:199-207.
134. Fuss IJ, Neurath M, Boirivant M, Klein JS, De La Motte C, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261-70.
135. Nalleweg N, Chiriac MT, Podstawa E, Lehmann C, Rau TT, Atreya R, et al. IL-9 and its receptor are predominantly involved in the pathogenesis of UC. Gut. 2015;64:743-55.
136. Mudter J, Yu J, Zufferey C, Brüstle A, Wirtz S, Weigmann B, et al. IRF4 regulates IL-17A promoter activity and controls RORt-dependent Th17 colitis in vivo. Inflamm Bowel Dis. 2011;17:1343-58.
137. Gerlach K, Hwang Y, Nikolaev A, Atreya R, Dornhoff H, Steiner S, et al. TH9 cells that express the transcription factor PU. 1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. 2014;15:676-86.
138. Gerlach K, McKenzie AN, Neurath MF, Weigmann B. IL-9 regulates intestinal barrier function in experimental T cell mediated colitis. Tissue Barriers. 2015;3:e983777.
139. Licona-Limón P, Henao-Mejia J, Temann AU, Gagliani N, Licona-Limón I, Ishigame H, et al. Th9 cells drive host immunity against gastrointestinal worm infection. Immunity. 2013;39:744-57.
140. Turner J-E, Morrison PJ, Wilhelm C, Wilson M, Ahlfors H, Renauld J-C, et al. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in Helminth-induced lung inflammation. J Exp Med. 2013;210:2951-65.
141. Pang N, Zhang F, Ma X, Zhang Z, Zhao H, Xin Y, et al. Th9/IL-9 profile in human echinococcosis: their involvement in immune response during infection by Echinococcus granulosus. Mediat Inflamm. 2014;2014:781649.
142. Khan W, Richard M, Akiho H, Blennerhasset P, Humphreys N, Grencis R, et al. Modulation of intestinal muscle contraction by interleukin-9 (IL-9) or IL-9 neutralization: correlation with worm expulsion in murine nematode infections. Infect Immun. 2003;71:2430-8.
143. Faulkner H, Renauld J-C, Van Snick J, Grencis R. Interleukin9 enhances resistance to the intestinal nematode Trichuris muris. Infect Immun. 1998;66:3832-40.
144. Richard M, Grencis RK, Humphreys NE, Renauld J-C, Van Snick J. Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc Natl Acad Sci U S A. 2000;97:767-72.
145. Anuradha R, George PJ, Hanna LE, Chandrasekaran V, Kumaran P, Nutman TB, et al. IL-4-, TGF--, and IL-1-dependent expansion of parasite antigen-specific Th9 cells is associated with clinical pathology in human lymphatic filariasis. J Immunol. 2013;191:2466-73.
146. Anuradha R, Munisankar S, Bhootra Y, Jagannathan J, Dolla C, Kumaran P, et al. IL-10- and TGFbeta-mediated Th9 responses in a human Helminth infection. PLoS Negl Trop Dis. 2016;10:e0004317.
147. Wu B, Huang C, Kato-Maeda M, Hopewell PC, Daley CL, Krensky AM, et al. IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. Clin Immunol. 2008;126:202-10.
148. Grohmann U, Van Snick J, Campanile F, Silla S, Giampietri A, Vacca C, et al. IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-, IL-12, and IFN-, and induction of IL-10. J Immunol. 2000;164:4197-203.
149. Pilette C, Ouadrhiri Y, Van Snick J, Renauld J-C, Staquet P, Vaerman J-P, et al. IL-9 inhibits oxidative burst and TNF- release in lipopolysaccharide-stimulated human monocytes through TGF-. J Immunol. 2002;168:4103-11.
150. Yang XR, Pfeiffer RM, Wheeler W, Yeager M, Chanock S, Tucker MA, et al. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. Int J Cancer. 2009;125:2912-7.
151. Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, et al. Robust tumor immunity to melanoma mediated by interleukin-9 producing T cells. Nat Med. 2012;18: 1248-53.
152. Fang Y, Chen X, Bai Q, Qin C, Mohamud AO, Zhu Z, et al. IL-9 inhibits HTB-72 melanoma cell growth through upregulation of p21 and TRAIL. J Surg Oncol. 2015;111:969-74.
153. Abdul-Wahid A, Cydzik M, Prodeus A, Alwash M, Stanojcic M, Thompson M, et al. Induction of antigen-specific TH 9 immunity accompanied by mast cell activation blocks tumor cell engraftment. Int J Cancer. 2016;139:841-53.
154. Lu Y, Hong S, Li H, Park J, Hong B, Wang L, et al. Th9 cells promote antitumor immune responses in vivo. J Clin Invest. 2012;122:4160.
155. Park J, Li H, Zhang M, Lu Y, Hong B, Zheng Y, et al. Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy. Cancer Immunol Immunother. 2014;63:835-45.
156. Miao B-P, Zhang R-S, Sun H-J, Yu Y-P, Chen T, Li L-J, et al. Inhibition of squamous cancer growth in a mouse model by Staphylococcal enterotoxin B-triggered Th9 cell expansion. Cell Mol Immunol. 2017;14:371-9.
157. Merz H, Houssiau F, Orscheschek K, Renauld J-C, Fliedner A, Herin M, et al. Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin’s disease and large cell anaplastic lymphoma. Blood. 1991;78:1311-7.
158. Tan H, Wang S, Zhao L. A tumour-promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways. Clin Exp Pharmacol Physiol. 2017;44:213-21.
159. Lange K, Uckert W, Blankenstein T, Nadrowitz R, Bittner C, Renauld J-C, et al. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene. 2003;22:517-27.
160. Simonovic SZ, Mihaljevic O, Majstorovic I, Djurdjevic P, Kostic I, Djordjevic OM, et al. Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer: elevated Th2/Th9 cytokine production before and reduced Th2 cytokine production after radioactive iodine therapy. Cancer Immunol Immunother. 2015;64:75-82.
161. Vink A, Renauld JC, Warnier G, Van Snick J. Interleukin-9 stimulates in vitro growth of mouse thymic lymphomas. Eur J Immunol. 1993;23:1134-8.
162. Chen N, Lu K, Li P, Lv X, Wang X. Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia. Int J Clin Exp Pathol. 2014;7:2319.
163. Smith SE, Hoelzinger DB, Dominguez AL, Van Snick J, Lustgarten J. Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunol Immunother. 2011;60:1775-87.
164. Ganjalikhani-Hakemi M, Yazdani R, Sherkat R, Homayouni V, Masjedi M, Hosseini M. Evaluation of the T helper 17 cell-specific genes and the innate lymphoid cells counts in the peripheral blood of patients with the common variable immunodeficiency. J Res Med Sci. 2014;19 Suppl. 1:S30-5.
165. Azizi G, Rezaei N, Kiaee F, Tavakolinia N, Yazdani R, Mirshafiey A, et al. T-cell abnormalities in common variable immunodeficiency. J Investig Allergol Clin Immunol. 2016;4: 233-43.
166. Yazdani R, Fatholahi M, Ganjalikhani-Hakemi M, Abolhassani H, Azizi G, Hamid KM, et al. Role of apoptosis in common variable immunodeficiency and selective immunoglobulin A deficiency. Mol Immunol. 2016;71:1-9.
167. Yazdani R, Ganjalikhani-Hakemi M, Esmaeili M, Abolhassani H, Vaeli S, Rezaei A, et al. Impaired Akt phosphorylation in B-cells of patients with common variable immunodeficiency. Clin Immunol. 2017;175:124-32.
168. Azizi G, Ahmadi M, Abolhassani H, Yazdani R, Mohammadi H, Mirshafiey A, et al. Autoimmunity in primary antibody deficiencies. Int Arch Allergy Immunol. 2016;171:180-93.
169. Azizi G, Abolhassani H, Asgardoon MH, Alinia T, Yazdani R, Mohammadi J, et al. Autoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management. Expert Rev Clin Immunol. 2017;13:101-15.
170. Yazdani R, Latif A, Tabassomi F, Abolhassani H, Azizi G, Rezaei N, et al. Clinical phenotype classification for selective immunoglobulin A deficiency. Expert Rev Clin Immunol. 2015;11:1245-54.
171. Petrella TM, Tozer R, Belanger K, Savage KJ, Wong R, Smylie M, et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol. 2012;30:3396-401.
172. Végran F, Apetoh L, Ghiringhelli F. Th9 cells: a novel CD4 Tcell subset in the immune war against cancer. Cancer Res. 2015;75:475-9.
173. Zhou Y, McLane M, Levitt RC. Th2 cytokines and asthma-interleukin-9 as a therapeutic target for asthma. Respir Res. 2001;2:80.
174. Barnes PJ. Cytokine modulators as novel therapies for asthma. Annu Rev Pharmacol Toxicol. 2002;42:81-98.
175. Jabeen R, Kaplan MH. The symphony of the ninth: the development and function of Th9 cells. Curr Opin Immunol. 2012;24:303-7.
176. Uyttenhove C, Simpson RJ, Van Snick J. Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. Proc Natl Acad Sci U S A. 1988;85:6934-8.
177. Townsend MJ, Fallon PG, Matthews DJ, Smith P, Jolin HE, McKenzie AN. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity. 2000;13:573-83.
178. Matsuzawa S, Sakashita K, Kinoshita T, Ito S, Yamashita T, Koike K. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol. 2003;170:3461-7.
179. Fujiki H, Kimura T, Minamiguchi H, Harada S, Wang J, Nakao M, et al. Role of human interleukin-9 as a megakaryocyte potentiator in culture. Exp Hematol. 2002;30:1373-80.
180. Gounni AS, Hamid Q, Rahman SM, Hoeck J, Yang J, Shan L. IL-9-mediated induction of eotaxin1/CCL11 in human airway smooth muscle cells. J Immunol. 2004;173:2771-9.
181. Dardalhon V, Collins M, Kuchroo VK. Physical attraction of Th9 cells is skin deep. Ann Transl Med. 2015;3:74.
182. Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC, et al. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol. 2000;105:108-15.
Article Sidebar
Published
Feb 15, 2019
Article Details
How to Cite
Yazdani, R., Shapoori, S., Rezaeepoor, M., Sanaei, R., Ganjalikhani-Hakemi, M., Azizi, G., Rae, W., Aghamohammadi, A., & Rezaei, N. (2019). Features and roles of T helper 9 cells and interleukin 9 in immunological diseases. Allergologia Et Immunopathologia, 47(1), 90-104. https://www.all-imm.com/index.php/aei/article/view/346
Issue
Section
Review Article
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Yazdani, R., Shapoori, S., Rezaeepoor, M., Sanaei, R., Ganjalikhani-Hakemi, M., Azizi, G., Rae, W., Aghamohammadi, A., & Rezaei, N. (2019). Features and roles of T helper 9 cells and interleukin 9 in immunological diseases. Allergologia Et Immunopathologia, 47(1), 90-104. https://www.all-imm.com/index.php/aei/article/view/346